SLC5A2 and diabetes mellitus: By decreasing sodium reabsorption, SGLT2 inhibitors increase tubuloglomerular feedback, leading to afferent arteriolar constriction and a subsequent reduction in glomerular hyperfiltration—a key driver of progressive nephron injury in both diabetic and non-diabetic kidney disease [65].